A clinically controlled trial will determine whether PCI in appropriate patients with left main disease is as good or superior to CABG, said Gregg W. Stone, MD, of the Columbia University Medical Center in New York City, during a presentation at the fourth annual Left Main and Bifurcation Summit April 29 in Seoul, South Korea, sponsored by the Cardiovascular Research Foundation (CRF).

Compared to the Taxus Express paclitaxel-eluting stents, the Xience V everolimus-eluting stents proved more effective for patients with coronary artery disease and significantly reduced rates of target-lesion failure (TLF) at one-year, according to a study published May 5 in the New England Journal of Medicine.

Boston Scientific has reported sharply wider net losses for 2010 first quarter, which ended March 31.

Boston Scientific has launched the Kinetix Guidewire, an interventional device that is used during PCI, which is equipped with a micro-cut nitinol sleeve.

Telehealth, this months cover story topic, has taken the national policy spotlight recently thanks to provisions of the National Healthcare Reform legislation and the American Recovery and Reinvestment Act of 2009.

OrbusNeich Medical, a developer and marketer of medical devices for the treatment of cardiovascular diseases, was granted U.S. Patent No. 7,682,384 B2, entitled Stent with Helical Elements, relating to an expandable stent comprised of a plurality of helical segments.

After more than one month of playing the waiting game, Boston Scientific has received the green light from the FDA to continue shipments of its Cognis cardiac resynchronization therapy defibrillators (CRT-D) and Teligen implantable cardioverter-defibrillators (ICDs).

Patients who do not have healthcare insurance, or those with insurance but other financial concerns about accessing healthcare, are more likely to delay seeking emergency care for a heart attack, according to a study in the April 14 issue of Journal of the American Medical Association.